About
Technology
Issues
FAQ
Links
Official Page
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.